AVIR
Atea Pharmaceuticals, Inc.
$5.43
+1.31%
2026-08-21
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Key Fundamentals
Forward P/E
-3.46
EPS (TTM)
$-2.08
ROE
-58.1%
Profit Margin
0.0%
Debt/Equity
0.21
Price/Book
2.01
Beta
0.27
Market Cap
$410.6M
Avg Volume (10D)
292K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.64
60D Low
$3.82
Avg Volume
330K
Latest Close
$5.43
Get breakout alerts for AVIR
Sign up for Breakout Scanner to receive daily notifications when AVIR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Atea Pharmaceuticals, Inc. (AVIR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AVIR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AVIR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.